Linked Life Data

21450329

Source:http://linkedlifedata.com/resource/pubmed/id/21450329

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2011-9-29
pubmed:abstractText
Beclin 1 plays a critical role not only in autophagy, but also in apoptosis and differentiation. The prognostic significance of beclin 1 in diffuse large B-cell lymphoma is largely unexplored. Immunohistochemical protein expression of beclin 1 in 118 tumor specimens from patients newly diagnosed with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen from 2003 to 2007 was analyzed. Beclin 1 expression was observed in 101 (85.6%) patients. Low beclin 1 expression was related to B symptoms (P = .018), advanced Ann Arbor stage (P = .009), International Prognostic Index of 2 or higher (P = .049), elevated serum lactate dehydrogenase level (P = .037), and poor outcome using the revised International Prognostic Index model (P = .013). The complete remission rate after standard treatment was higher in patients with high beclin 1 expression than in those with low beclin 1 expression (77.5% versus 55.3%, P = .013). Beclin 1 expression was inversely associated with bcl-2 expression (P = .019) and positively associated with longer overall survival (P = .035) and progression-free survival (P = .013). In multivariate analysis, beclin 1 expression and the revised International Prognostic Index model independently predicted survival. The proposed clinicopathologic prognostic model including these 2 independent prognostic factors allowed classification of patients into 3 risk groups (P < .0001, respectively). Beclin 1 expression predicts superior clinical outcome in patients with diffuse large B-cell lymphoma treated with standard treatment. The novel prognostic model which divides patients with diffuse large B-cell lymphoma into different risk categories may help guide treatment planning.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1532-8392
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1459-66
pubmed:meshHeading
pubmed-meshheading:21450329-Adult, pubmed-meshheading:21450329-Aged, pubmed-meshheading:21450329-Aged, 80 and over, pubmed-meshheading:21450329-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:21450329-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:21450329-Apoptosis Regulatory Proteins, pubmed-meshheading:21450329-Cyclophosphamide, pubmed-meshheading:21450329-Disease-Free Survival, pubmed-meshheading:21450329-Doxorubicin, pubmed-meshheading:21450329-Female, pubmed-meshheading:21450329-Humans, pubmed-meshheading:21450329-Kaplan-Meier Estimate, pubmed-meshheading:21450329-Lymphoma, Large B-Cell, Diffuse, pubmed-meshheading:21450329-Male, pubmed-meshheading:21450329-Membrane Proteins, pubmed-meshheading:21450329-Middle Aged, pubmed-meshheading:21450329-Predictive Value of Tests, pubmed-meshheading:21450329-Prednisone, pubmed-meshheading:21450329-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:21450329-Risk Assessment, pubmed-meshheading:21450329-Tumor Markers, Biological, pubmed-meshheading:21450329-Vincristine, pubmed-meshheading:21450329-Young Adult
pubmed:year
2011
pubmed:articleTitle
Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
pubmed:affiliation
State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University, Guangzhou, Guangdong, PR China 510060.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't